TY - JOUR
T1 - Calcitriol for Congenital Osteopetrosis
AU - Blazar, Bruce R.
AU - Fallon, Michael D.
AU - Teitelbaum, Steven L.
AU - Ramsay, Norma K.C.
AU - Brown, David M.
AU - Key, L. Lyndon
AU - Anast, Constantine S.
PY - 1984/7/5
Y1 - 1984/7/5
N2 - To the Editor: Key et al. (Feb. 16 issue)1 describe an infant with malignant osteopetrosis who had a small clinical response to highdose calcitriol (32 μg per day). A morphologic and functional change in osteoclasts was noted. We have administered high-dose calcitriol (24 μg per day) to two infants with malignant osteopetrosis. The first presented at the age of two months with mild frontal bossing, cranial-nerve dysfunction, massive hepatosplenomegaly, pallor, and developmental delay. Biochemical aberrations before therapy included elevated serum levels of parathyroid hormone, acid phosphatase, and 1,25-dihydroxyvitamin D and decreased levels of serum calcium and phosphorus. The second infant,.
AB - To the Editor: Key et al. (Feb. 16 issue)1 describe an infant with malignant osteopetrosis who had a small clinical response to highdose calcitriol (32 μg per day). A morphologic and functional change in osteoclasts was noted. We have administered high-dose calcitriol (24 μg per day) to two infants with malignant osteopetrosis. The first presented at the age of two months with mild frontal bossing, cranial-nerve dysfunction, massive hepatosplenomegaly, pallor, and developmental delay. Biochemical aberrations before therapy included elevated serum levels of parathyroid hormone, acid phosphatase, and 1,25-dihydroxyvitamin D and decreased levels of serum calcium and phosphorus. The second infant,.
UR - http://www.scopus.com/inward/record.url?scp=0021268456&partnerID=8YFLogxK
U2 - 10.1056/NEJM198407053110116
DO - 10.1056/NEJM198407053110116
M3 - Letter
C2 - 6547208
AN - SCOPUS:0021268456
SN - 0028-4793
VL - 311
SP - 55
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 1
ER -